Label: HYDRO-Q- hydroquinone gel
- NDC Code(s): 30815-0040-1
- Packager: Dermavance Pharmaceuticals
- Category: HUMAN PRESCRIPTION DRUG LABEL
DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Drug Label Information
Updated January 12, 2023
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- SPL UNCLASSIFIED SECTION
-
DESCRIPTION
HYDRO-Q® contains hydroquinone USP 4%. Hydroquinone is 1, 4-Benzenediol {CAS 123-31-91}. Hydroquinone is structurally related to monobenzone. Hydroquinone occurs as fine white needles. The drug is freely soluble in water and in alcohol and has a pKa of 9.96. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C6H6O2; The molecular weight is 110.1. The structural formula is:
- ACTIVE INGREDIENT
-
CLINICAL PHARMACOLOGY
Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic hydroquinone. oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (dopa) 1 and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause regimentation of the bleached areas.
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
-
WARNINGS
- CAUTION: Hydroquinone is a depigmenting agent that may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.
- Test for skin sensitivity before using HYDRO-Q® by applying a small amount of the gel to an unbroken patch of skin and check within 24 hours. Minor redness is not a contraindication but where there is itching and vesicle formation or excessive inflammatory response further treatment is not advised. Close patient supervision is recommended. Contact with the eyes should be avoided. If no lightening effect is noted after 2 months of treatment the use of HYDRO-Q® should be discontinued. HYDRO-Q® is formulated for the treatment of dyschromia and should not be used for the prevention of sunburn.
- Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight sustains melanocytic activity. To prevent repigmentation during treatment and maintenance therapy, sun exposure on treated skin should be avoided by application of a broad spectrum sunscreen SPF 15 or greater) or by use of protective clothing
- Keep this and all medications out of reach of children. In case of accidental ingestion, contact a physician or a poison control center immediately.
- WARNING: Contains sodium metabisulfite, a sulfite that may cause serious allergic reactions (e.g., hives, itching, wheezing, anaphylaxis, severe asthma attack) in certain susceptible persons
- On rare occasions, a gradual blue-black darkening of the skin may occur, in which case, use of HYDRO-Q® should be discontinued and a physician contacted immediately
-
PRECAUTIONS
See Warnings
A. Pregnancy Category C
Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman, or can affect reproductive capacity.
- ADVERSE REACTIONS
- OVERDOSAGE
-
DOSAGE AND ADMINSTRATION
HYDRO-Q® should be applied to the affected areas twice daily, morning and before bedtime or as directed by a physician.
During and after the use of HYDRO-Q®, sun exposure should be limited and a sunscreen agent or protective clothing should be used to cover up the treated areas to prevent regimentation. If no lightening effect is noted after two months of treatment, use of HYDRO-Q® should be discontinued. There is no recommended dosage for children under the age of 12 years of age except under the advice and supervision of a physician.
- HOW SUPPLIED
-
REFERENCES
- Denton C, Fitzpatrick TB, Lerner AB. Inhibition of melanin formation by chemical agents. J Invest Dermatology. 1952; 18: 119-135.
- Fitzpatrick TB, Jimbow K, Obata M, Panthak M. Mechanism of depigmentation by hydroquinone. J Invest Dermatology. 1974; 62: 436-449.
- Anderson RR, Parrish JA, Pitts D, Urbach F. UVA, Biological Effects of Ultraviolet Radiation With Emphasis on Human Responses to Longwave Ultraviolet. New York and London: Plenum Press; 1978: 151.
- SPL UNCLASSIFIED SECTION
- PRINCIPAL DISPLAY PANEL - 30 g Tube Box
-
INGREDIENTS AND APPEARANCE
HYDRO-Q
hydroquinone gelProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:30815-0040 Route of Administration TOPICAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Hydroquinone (UNII: XV74C1N1AE) (Hydroquinone - UNII:XV74C1N1AE) Hydroquinone 40 mg in 1 g Inactive Ingredients Ingredient Name Strength Water (UNII: 059QF0KO0R) CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: 4Q93RCW27E) SODIUM METABISULFITE (UNII: 4VON5FNS3C) SODIUM HYDROXIDE (UNII: 55X04QC32I) METHYLPARABEN (UNII: A2I8C7HI9T) EDETATE DISODIUM (UNII: 7FLD91C86K) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:30815-0040-1 1 in 1 BOX 12/08/2008 1 30 g in 1 TUBE; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 12/08/2008 Labeler - Dermavance Pharmaceuticals (046042475) Establishment Name Address ID/FEI Business Operations Medical Products Laboratories, Inc. 002290302 MANUFACTURE(30815-0040)